FDA approves Trijardy XR (empagliflozin, linagliptin and metformin) for lowering blood sugar in adults with type 2 diabetes.

Approval was based on 2 RCTs that evaluated Trijardy XR and individual components in healthy adults. Safety profile was consistent with individual components. In UK, linagliptin is currently only available in combination with empagliflozin or metformin

Biospace Inc.